Evidence map›Paper›PMID 29590141›Full record

ArticlePloS one2018

Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban.

Blake Charlton, Gboyega Adeboyeje, John J Barron, Deborah Grady, Jaekyu Shin, Rita F Redberg

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03702582 (Trial of New Oral Anticoagulants vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03702582 phase3completednot on this mapstarted 2019, after this paper: background citation

Trial of New Oral Anticoagulants vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation

TypeinterventionalSponsorMassachusetts General HospitalRan2019 to 2023Enrolled100ConditionsAtrial Fibrillation, Stroke, BleedingArmsRivaroxaban, Warfarin
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Blake CharltonDepartment of Medicine, University of California San Francisco, San Francisco, CA, United States of America.ORCID 0000-0003-3461-1814
Gboyega AdeboyejeHealthCore, Inc, Wilmington, DE, United States of America.
John J BarronHealthCore, Inc, Wilmington, DE, United States of America.
Deborah GradyDepartment of Medicine, University of California San Francisco, San Francisco, CA, United States of America.
Jaekyu ShinDepartment of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, CA, San Francisco, CA, United States of America.
Rita F RedbergDepartment of Medicine, University of California San Francisco, San Francisco, CA, United States of America.
University of California, San Francisco · USWilmington University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDifferent outcomes among patients hospitalized for bleeding after starting anticoagulation could influence choice of anticoagulant. We compared length of hospitalization, proportion of Intensive Care Unit (ICU) admissions, ICU length of stay, and 30- and 90-day mortality for adults with atrial fibrillation hospitalized for bleeding after starting warfarin, dabigatran, or rivaroxaban.

methodsAn US commercial database of 38 million members from 1 November 2010 to 31 March 2014 was used to examine adults with atrial fibrillation hospitalized for bleeding after starting warfarin (2,446), dabigatran (442), or rivaroxaban (256). Outcomes included difference in mean total length of hospitalization, proportion of ICU admissions, mean length of ICU stay, and all-cause 30- and 90-day mortality.

resultsWarfarin users were older and had more comorbidities. Multivariable regression modeling with propensity score weighting showed warfarin users were hospitalized 2.0 days longer (95% CI 1.8-2.3; p < 0.001) than dabigatran users and 2.6 days longer (95% CI 2.4-2.9; p < 0.001) than rivaroxaban users. Dabigatran users were hospitalized 0.6 days longer (95% CI 0.2-1.0; p = 0.001) than rivaroxaban users. There were no differences in the proportion of ICU admissions. Among ICU admissions, warfarin users stayed 3.0 days (95% CI 1.9-3.9; p < 0.001) longer than dabigatran users and 2.4 days longer (95% CI 0.9-3.7; p = 0.003) than rivaroxaban users. There was no difference in ICU stay between dabigatran and rivaroxaban users. There were no differences in 30- and 90-day all-cause mortality.

conclusionsRivaroxaban and dabigatran were associated with shorter hospitalizations; however, there were no differences in 30- and 90-day mortality. These findings suggest bleeding associated with the newer agents is not more dangerous than bleeding associated with warfarin.

Indexed as

AgedAnticoagulantsAtrial FibrillationBlood CoagulationDabigatranFemaleHemorrhageHospitalizationHumansIntensive Care UnitsLength of StayMalePropensity ScoreRetrospective StudiesRivaroxabanWarfarinAnticoagulantsDabigatranRivaroxabanWarfarin

Identifiers

PMID29590141
PMCPMC5874024
OpenAlexW2794887391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.